More Articles Back to Article
Cancer drugs get faster approval in US than Europe
A cross-sectional study of 89 cancer drugs approved in the US and Europe from 2010 to 2019 showed that 95% of the drugs were first approved in the US. The study published in JAMA Network Open showed more cancer drugs were approved under expedited pathways in the US than Europe during the period, and the median review time was shorter in the US compared with Europe. Regulatory Focus (6/10)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!